Journal
JOURNAL OF CONTROLLED RELEASE
Volume 74, Issue 1-3, Pages 295-302Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/S0168-3659(01)00341-8
Keywords
doxorubicin; anticancer drug; drug targeting; polymeric micelle
Ask authors/readers for more resources
We show the result of pre-clinical study of NK911, a polymeric micelle carrier system for doxorubicin (DOX). The NK911 micelle carrier consists of polyethyleneglycol and conjugated doxorubicin-polyaspartic acid. It has high hydrophobic inner core, and therefore can entrap the sufficient amount of DOX. NK911 has a small particle size of about 40 nm in diameter that accumulates in tumor tissue by EPR effect showing much stronger activity than the free DOX. We plan to perform a clinical trial at National Cancer Center Hospital, Japan from 2001. (C) 2001 Elsevier Science BY. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available